NuGen Announces Proposed Private Placement of up to $10 million Secured Convertible Debentures

Rhea-AI Summary

NuGen Medical Devices (TSXV: NGMD) announced a non-brokered private placement of up to $10 million in secured convertible debentures. The debentures mature in five years and bear a 12% annual interest rate, payable at maturity. They are secured by the company's assets and can be converted into units priced at $0.075 each, which include one common share and a purchase warrant exercisable at $0.12 for five years. Proceeds will fund working capital, production expansion, and order fulfillment. Sol-Millennium Medical Group is expected to become a controlling shareholder, pending approval at NuGen's August 20, 2024 shareholder meeting.

Positive

• Proposed private placement of up to $10 million secured convertible debentures.
• Debentures bear a 12% annual interest rate, payable at maturity.
• Proceeds to be used for working capital, production expansion, and fulfilling global purchase orders.
• Convertible debentures can be converted into units priced at $0.075 with purchase warrants exercisable at $0.12.

Negative

• Creation of a new control person requires shareholder approval, introducing potential uncertainty.

Toronto, Ontario--(Newsfile Corp. - July 10, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce its intention to complete a non-brokered private placement (the "Offering") of up to $10,000,000 principal amount secured convertible debentures (the "Convertible Debentures"). The Convertible Debentures shall mature on the date that is five (5) years from the closing of the Offering (the "Maturity Date") and shall bear interest at a rate of 12% per annum payable on the Maturity Date in arrears. The Convertible Debentures will be secured by a first ranking security interest in all of the present and after-acquired property and assets of the Company pursuant to a general security agreement which shall include standard default conditions customary for a transaction of this nature.

The Company intends to use the proceeds from the Offering for working capital purposes, expansion of production and fulfillment of increasing sale purchase orders globally.

At any time prior to the close of business on the last business day immediately preceding the Maturity Date, the holder shall have the right, at the holder's option, to convert all or a portion of the outstanding principal amount of the Convertible Debentures into units of the Company (the "Units") at a price of $0.075 per Unit. Each Unit shall be comprised of one common share in the capital of the Company (each, a "Common Share") and one Common Share purchase warrant exercisable at a price of $0.12 per Common Share for a period of five years from the closing of the Offering.

The issuance of the Convertible Debentures pursuant to the Offering will be (and, if applicable, the issuance of the underlying Units upon conversion of the Convertible Debentures shall be) completed on a private placement and prospectus exempt basis.

Closing of the Offering is subject to receipt of all necessary corporate and regulatory approvals, including the approval of TSX Venture Exchange (the "TSXV"). All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.

It is anticipated that Sol-Millennium Medical Group or its affiliates ("Sol-M") will purchase that number of Convertible Debentures that, if and when converted into Units, would result in Sol-M holding greater than 20% of the then issued and outstanding Common Shares thereby making Sol-M a new Control Person (as defined in the policies of the TSXV) of the Company under applicable securities laws. Pursuant to the policies of the TSXV, the creation of a new Control Person of the Company requires shareholder approval. Consequently, the Company intends to obtain shareholder approval at its upcoming annual and special meeting of its shareholders to be held on August 20, 2024.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About NuGen

NuGen is a leading developer of needle-free devices to administer therapeutics subcutaneously. The Company is marketing and selling its next-generation InsuJet™ needle-free injection system designed to improve the lives of millions of diabetics. InsuJet™ is approved for sale in 42 countries around the world.

About Sol-M

Sol-M is one of the world's largest manufacturers of needles and syringes. It is vertically integrated with locations across the globe. Sol-Millennium's innovative technology helps positive patient outcomes, saves on medication, and enhances both clinician and patient experience. With an international sales team dedicated to delivering knowledge and outstanding customer service, Sol-Millennium's goal is to partner with those in healthcare, focusing on a healthier tomorrow.

For further information, please visit:

Websites: www.insujet.com, www.nugenmd.com, www.solm.com, and www.solm.com/insujet/

Instagram: @NuGenMD

Twitter: @NuGenMD

LinkedIn: https://www.linkedin.com/company/nugenmd/
and www.linkedin.com/company/sol-millennium-medical-group/

For further information, please contact:

Tony Di Benedetto
Executive Chairman
(416) 791-9399
tony@nugenmd.com

Ian Heynen
CEO
(416) 560-1019
ian@nugenmd.com

To arrange a media interview with NuGen, please contact:

Morna Gorman
(416) 553-1732
morna@nugenmd.com

Notice Regarding Forward-Looking Information:

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/216117

FAQ

What is the proposed private placement by NuGen Medical Devices?

NuGen Medical Devices proposed a private placement of up to $10 million secured convertible debentures.

What is the interest rate on NuGen's convertible debentures?

The convertible debentures bear an annual interest rate of 12%, payable at maturity.

What will NuGen use the proceeds from the offering for?

NuGen will use the proceeds for working capital, production expansion, and fulfilling increasing global purchase orders.

At what price can the convertible debentures be converted into units?

The debentures can be converted into units at a price of $0.075 each.

What is included in each unit when converting the debentures?

Each unit includes one common share and one common share purchase warrant exercisable at $0.12 for a period of five years.

When is the shareholder meeting to approve the new control person for NuGen?

The shareholder meeting to approve the new control person is scheduled for August 20, 2024.

Which group is expected to become the controlling shareholder of NuGen?

Sol-Millennium Medical Group is expected to become the controlling shareholder, pending shareholder approval.